La radiothérapie des cancers du poumon non à petites cellules localement avancés

Abstract

For patients with locally advanced unresectable non-small cell lung cancer, the standard treatment is a combination of chemotherapy and radiation therapy, preferably concurrent, followed by consolidation immunotherapy with durvalumab. The challenge is to administer radiation therapy that is effective enough without the risk of unacceptable toxicity: defining the optimal dose and volumes, implementing modern radiation therapy techniques in routine, and taking into account all organs at risk (OAR), including some that have not been considered until now, these are the major issues of quality thoracic radiation therapy.